CETP Genotype (p.Arg468Gln)

Most people get their cholesterol checked and never ask why one person's HDL runs stubbornly low while another's runs high on the same lifestyle. A small piece of that answer is written in your genes, in a protein called CETP that decides how cholesterol moves between particles in your blood. The p.Arg468Gln variant of the CETP gene turns up the dial on that protein, leaving you with less good cholesterol and, when severe infection strikes, worse odds of surviving it.

This is a one-time test. You inherit your CETP status at birth and carry it for life, so a single buccal swab or blood draw gives you an answer that never changes. What does change is what you do with that information, especially if standard lipid testing has been hinting at a problem you could not explain.

What This Variant Actually Does

CETP (cholesteryl ester transfer protein) is made mainly by the liver and circulates in your blood. Its job is to swap cholesterol out of HDL (high-density lipoprotein, the good cholesterol) and into LDL (low-density lipoprotein, the bad cholesterol) and other fat-carrying particles. The more active CETP is, the lower your HDL tends to run and the more cholesterol ends up in the particles that drive plaque buildup.

The p.Arg468Gln variant (also reported as p.Arg451Gln in older literature that numbers from the mature protein, and known to geneticists as rs1800777) is a gain-of-function change. Even in healthy non-sepsis populations, carriers have about 22% higher CETP concentration, roughly 13% higher CETP activity, and around 6% lower HDL cholesterol than non-carriers. In sepsis cohorts, that same pattern of lower HDL and higher CETP mass shows up in the setting where outcomes hinge most on it.

Severe Infection Outcomes

The strongest signal for this specific variant is in sepsis, the body-wide reaction to severe infection. Across multiple human cohorts including UK Biobank, Copenhagen population studies, and intensive care unit cohorts, carriers of p.Arg468Gln had higher 28-day mortality after a sepsis episode than non-carriers, with a hazard ratio around 1.44 in the pooled analysis.

In a separate study of adults with sepsis, carriers had abnormally low HDL, higher CETP mass, and a significantly increased risk of sepsis-associated AKI (acute kidney injury, where the kidneys fail during the infection). The same pattern, that less CETP activity tracks with better sepsis survival, has been confirmed using a broader genetic score for reduced CETP function.

What this means for you: if you know you carry this variant and you ever develop a serious infection requiring hospitalization, the risk math is not in your favor. There is no specific treatment that targets this variant during sepsis today, but knowing you sit in a higher-risk group is a reason to act early on any infection that feels like it is escalating rather than wait it out at home.

Heart Disease and Cholesterol

Direct evidence of subclinical atherosclerosis in carriers comes from the Multi-Ethnic Study of Atherosclerosis. Carriers of this variant had significantly higher coronary artery calcium and more carotid artery plaque than non-carriers, even after adjusting for traditional risk factors and HDL itself. Higher CETP activity moves cholesterol from HDL toward LDL and apoB (apolipoprotein B, the structural protein on bad cholesterol particles), the very pattern that drives plaque buildup. In a separate genetic analysis of CETP concentration, higher genetically determined CETP lowered HDL meaningfully and raised the odds of coronary artery disease.

Coming from the other direction, people who carry CETP variants that lower CETP function (truncating variants, the TaqIB B2 allele, and CETP-deficiency alleles) tend to have higher HDL, lower LDL, and reduced risk of coronary heart disease across multiple analyses. So if reduced CETP activity protects, increased CETP activity, which is what p.Arg468Gln produces, sits on the wrong side of that line.

Reconciling Two Apparent Contradictions

It can look paradoxical that lifelong genetically lower CETP protects against heart disease but raises the risk of age-related macular degeneration, the eye condition that erodes central vision with age. That trade-off applies to people who inherit reduced CETP activity. The p.Arg468Gln variant runs CETP activity in the opposite direction. Carriers do not get the heart protection of low CETP, but they also do not inherit the elevated AMD risk that travels with it. For this variant, the read is straightforward: lower HDL, a more atherogenic shift in cholesterol distribution, and worse sepsis outcomes, with no offsetting upside in eye health to weigh against them.

Why One Test Is Enough

Genetic tests do not need retesting. Your CETP genotype is set at conception and stays the same through life. A single confirmed result gives you a permanent answer. What does need tracking is the downstream phenotype: how this variant is shaping your HDL, your LDL, your apoB, and your Lp(a). Those numbers change with age, lifestyle, and medication, and they are the levers you can actually pull.

If you test positive for the variant, a sensible cadence is a full lipid workup now, including apoB and Lp(a), and a repeat at 6 to 12 months if you are making changes or starting therapy, then annually after that. The goal is not to chase the genotype, it is to chase the lipid pattern the genotype tends to produce.

What to Do With a Positive Result

There is no medication that targets this specific variant or reverses its effect. What you can do is treat the lipid pattern it tends to produce as if it deserves more attention, not less. If your HDL runs low or your apoB runs high, that should be enough to push you toward an aggressive workup rather than a wait-and-see approach. A lipidologist or preventive cardiologist is the right specialist to consult if your numbers and your variant together suggest elevated cardiovascular risk, especially if you also have a family history of early heart attacks.

On the infection side, knowing your status does not change daily life, but it is information worth having on file. If you are ever admitted for sepsis or a severe infection, knowing you carry a variant linked to worse outcomes in that setting is the kind of detail a thoughtful intensivist may want to know, even though no genotype-specific treatment exists yet.